RecruitingNCT04850729

Relationship Between Perioperative Treatment Efficacy and The Tumor Microenvironment for Locally Advanced Resectable Gastric Cancer.

An Observational Study of Relationship Between Perioperative Treatment Efficacy and The Tumor Microenvironment for Locally Advanced Resectable Gastric and Gastro-oesophageal Junction Adenocarcinoma


Sponsor

Nanfang Hospital, Southern Medical University

Enrollment

169 participants

Start Date

May 25, 2021

Study Type

OBSERVATIONAL

Conditions

Summary

Perioperative drug treatment has gradually become the standard regimen for locally advanced gastric cancer, whereas only a subset of patients could benefit from it. Therefore, one major challenge for perioperative drug treatment is to construct promising biomarkers and to screen out potential beneficial patients. Recent evidence has revealed that tumor microenvironment (TME) is highly associated with the prognosis of gastric cancer. Meanwhile, tumor microenvironment score (TMEscore) established with transcriptomic data is a robust biomarker for predicting prognosis and guiding individualized immunotherapy strategies. However, its predictive value for perioperative drug treatment outcomes warrants further exploration and validation. The study is a multi-center, observational study to evaluate the relationship between the efficacy of perioperative treatment and tumor microenvironment in patients with locally advanced resectable gastric and gastro-oesophageal junction adenocarcinoma, aiming at further determining the predictive value of TMEscore and establishing a comprehensive treatment-efficacy evaluation system for gastric cancer.


Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study looks at how the tumor's surrounding environment (the cells and molecules around the cancer) relates to how well treatment works in people with advanced stomach or esophageal cancer who are having surgery. **You may be eligible if...** - You have been diagnosed with locally advanced stomach or esophageal junction cancer (confirmed by biopsy) - You are between 18 and 75 years old - You are willing to provide leftover tumor tissue from your routine diagnosis - You agree to participate and sign the consent form **You may NOT be eligible if...** - Your cancer has spread to distant organs - You do not meet the specific cancer staging requirements Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERnon-intervention

non-intervention


Locations(1)

Nanfang Hospital, Southern Medical University

Guangzhou, Guangdong, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04850729


Related Trials